These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10379694)

  • 1. Effect of investigator bias on the power and level of the two-sample Z-test.
    DeLucca P; Raghavarao D; Altan S
    J Biopharm Stat; 1999 May; 9(2):279-88. PubMed ID: 10379694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of investigator bias on the significance level of the Wilcoxon rank-sum test.
    DeLucca P; Raghavarao D
    Biostatistics; 2000 Mar; 1(1):107-11. PubMed ID: 12933528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical analysis of possible bias of clinical judgements due to observing an on-therapy marker variable.
    Boateng F; Sampson A; Schwab B
    Stat Med; 1996 Aug; 15(16):1747-55. PubMed ID: 8870157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Some reflexions about double blind].
    Boussageon R; Gueyffier F; Moreau A; Gansel Y; Boussageon V
    Encephale; 2008 Sep; 34(4):347-51. PubMed ID: 18922236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of clinical data with breached blindness.
    Chow SC; Shao J
    Stat Med; 2004 Apr; 23(8):1185-93. PubMed ID: 15083477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy evaluation for monotherapies in two-by-two factorial trials.
    Hung HM; Chi GY; O'Neill RT
    Biometrics; 1995 Dec; 51(4):1483-93. PubMed ID: 8589235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomizing research participants: promoting balance and concealment in small samples.
    Matthews EE; Cook PF; Terada M; Aloia MS
    Res Nurs Health; 2010 Jun; 33(3):243-53. PubMed ID: 20499394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinded assessment of treatment effects utilizing information about the randomization block length.
    Miller F; Friede T; Kieser M
    Stat Med; 2009 May; 28(12):1690-706. PubMed ID: 19340815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Weighting in instrumental variables and G-estimation.
    Joffe MM; Brensinger C
    Stat Med; 2003 Apr; 22(8):1285-303. PubMed ID: 12687655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjusting for observable selection bias in block randomized trials.
    Ivanova A; Barrier RC; Berger VW
    Stat Med; 2005 May; 24(10):1537-46. PubMed ID: 15723426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample size for comparing linear growth curves.
    Patel HI; Rowe E
    J Biopharm Stat; 1999 May; 9(2):339-50. PubMed ID: 10379697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using the instrumental variables estimator to analyze noninferiority trials with noncompliance.
    Kim MY
    J Biopharm Stat; 2010 Jul; 20(4):745-58. PubMed ID: 20496203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Who is blinded in randomized clinical trials? A study of 200 trials and a survey of authors.
    Haahr MT; Hróbjartsson A
    Clin Trials; 2006; 3(4):360-5. PubMed ID: 17060210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What random assignment does and does not do.
    Krause MS; Howard KI
    J Clin Psychol; 2003 Jul; 59(7):751-66. PubMed ID: 12808582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the statistical power of different methods for the analysis of cluster randomization trials with binary outcomes.
    Austin PC
    Stat Med; 2007 Aug; 26(19):3550-65. PubMed ID: 17238238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robustness and power of analysis of covariance applied to ordinal scaled data as arising in randomized controlled trials.
    Sullivan LM; D'Agostino RB
    Stat Med; 2003 Apr; 22(8):1317-34. PubMed ID: 12687657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomization model methods for evaluating treatment efficacy in multicenter clinical trials.
    Davis CS; Chung Y
    Biometrics; 1995 Sep; 51(3):1163-74. PubMed ID: 7548700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e302-4. PubMed ID: 15173052
    [No Abstract]   [Full Text] [Related]  

  • 20. The fallacy of enrolling only high-risk subjects in cancer prevention trials: is there a "free lunch"?
    Baker SG; Kramer BS; Corle D
    BMC Med Res Methodol; 2004 Oct; 4():24. PubMed ID: 15461821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.